Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

The Novel Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) Platform Identifies Synergistic Activity of Lanraplenib and Ruxolitinib in Hematological Malignancies

Akanksha Pandey, Luis A. Carvajal, Andrew S Boghossian, Matthew G Rees, Melissa M Ronan, Jennifer A Roth, Tressa Hood, Linlin Guo, Tamara D Hopkins, Nikolaus Obholzer, Michael R. McKeown, Jorge F. DiMartino, Charles Y. Lin

Blood (2023) 142 (Supplement 1): 2259.

https://doi.org/10.1182/blood-2023-174114

Published: 2023

Journal Articles

The Combination of Lanraplenib, a Selective SYK Inhibitor, and Gilteritinib, a FLT3 Inhibitor, Targets Aberrant Proliferation and Differentiation Blockade in Acute Myeloid Leukemia

Luis A. Carvajal, Michael R. McKeown, Tressa Hood, Linlin Guo, Charles Y. Lin, Jorge F. DiMartino

Blood (2023) 142 (Supplement 1): 5951.

https://doi.org/10.1182/blood-2023-186605

Published: 2023

Journal Articles

Gut Microbiome Faecalibacterium Abundance in Patients with Plasma Cell Disorders Undergoing Autologous Hematopoietic Stem Cell Transplant Is Associated with Progression Free Survival

Erin A. Dean, Arkaprava Roy, Rick Y. Lin, Raad Z. Gharaibeh, Derek M. Li, Josee Gauthier, Christian Jobin, Zeina A. Al-Mansour, John R. Wingard

Blood (2023) 142 (Supplement 1): 3596.

https://doi.org/10.1182/blood-2023-188119

Published: 2023

Journal Articles

Incidence and Outcomes of Cytomegalovirus Reactivation after Chimeric Antigen Receptor T Cell Therapy

Rick Y. Lin, Anthony Anderson, Mohammed Raja, Michele I. Morris, Antonio M. Jimenez Jimenez, Amer M. Beitinjaneh, Trent Wang, Mark S. Goodman, Lazaros J. Lekakis, Jay Y. Spiegel, Denise L. Pereira, Krishna V. Komanduri, Jose F. Camargo

Blood (2023) 142 (Supplement 1): 3516.

https://doi.org/10.1182/blood-2023-175081

Published: 2023

Journal Articles

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Blood (2023) 141 (23): 2841–2852.

https://doi.org/10.1182/blood.2022018885

Published: 2023

Includes: Supplemental data

Journal Articles

CDK7 Inhibition Targets Proliferative and Metabolic Oncogenic Vulnerabilities in Multiple Myeloma

Yao Yao, Jessica Fong Ng, Woojun D Park, Mehmet K. Samur, Eugenio Morelli, Nicholas P Kwiatkowski, Jessica Encinas Mayoral, Zuzana Chyra, Yan Xu, Behnam Nabet, Marta Chesi, Nathaniel Gray, Richard A. Young, Kenneth C. Anderson, Charles Y Lin, Nikhil C Munshi, Mariateresa Fulciniti

Blood (2022) 140 (Supplement 1): 9955–9956.

https://doi.org/10.1182/blood-2022-163811

Published: 2022

Journal Articles

Targeting a Putative Intronic Splicing Silencer Salvages Expression from the Recurrent SBDS C.258+2T>C Mutant Allele in Shwachman-Diamond Syndrome Patient Cells and Mouse Model

Blood (2022) 140 (Supplement 1): 2944–2945.

https://doi.org/10.1182/blood-2022-169379

Published: 2022

Journal Articles

Preclinical Characterization of NGM936, a Novel Bispecific T Cell Engager Targeting ILT3 for the Treatment of Acute Myeloid Leukemia with Monocytic Differentiation

Vicky Y Lin, Anjushree Iyer, Keith Akama, Rujin Cheng, Hong Yang, Jonathan Aguayo, Betty Li, Alan K Kutach, Jie Tang, Daniel Kaplan, Julie M Roda

Blood (2022) 140 (Supplement 1): 9063–9064.

https://doi.org/10.1182/blood-2022-160209

Published: 2022

Journal Articles

Increased COVID-19 breakthrough infection risk in patients with plasma cell disorders

Jennifer La, Julie Tsu-Yu Wu, Westyn Branch-Elliman, Linden Huhmann, Summer S. Han, Mary Brophy, Nhan V. Do, Albert Y. Lin, Nathanael R. Fillmore, Nikhil C. Munshi

Blood (2022) 140 (7): 782–785.

https://doi.org/10.1182/blood.2022016317

Published: 2022

Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Blood (2021) 138 (Supplement 1): 2448.

https://doi.org/10.1182/blood-2021-154490

Published: 2021

Journal Articles

Preclinical Activity of Selective SYK Inhibitors, Entospletinib and Lanraplenib, Alone or Combined with Targeted Agents in Ex Vivo AML Models with Diverse Mutational Backgrounds

Melinda A. L. Day, Philipp Sergeev, Caroline A. Heckman, Anna Schinzel, Nikolaus D. Obholzer, Charles Y. Lin, Pavan Kumar, Jorge DiMartino, Douglas C. Saffran

Blood (2021) 138 (Supplement 1): 3356.

https://doi.org/10.1182/blood-2021-146180

Published: 2021

Journal Articles

CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Krish Patel, Jeffrey A. Zonder, Dahlia Sano, Michael Maris, Alexander Lesokhin, Gottfried von Keudell, Catherine Lai, Rod Ramchandren, Tina Catalano, Gloria H. Y. Lin, Bob Uger, Penka S. Petrova, Naomi Molloy, Ingmar Bruns, Swaminathan P Iyer

Blood (2021) 138 (Supplement 1): 3560.

https://doi.org/10.1182/blood-2021-153683

Published: 2021

Journal Articles

Inadequate Sars-Cov-2 Vaccine Effectiveness in Patients with Multiple Myeloma: A Large Nationwide Veterans Affairs Study

Nathanael R Fillmore, Jennifer La, Julie Tsu-Yu Wu, Westyn Branch-Elliman, Linden Huhmann, Summer S Han, Giovanni Parmigiani, David P Tuck, Mary Brophy, Nhan V Do, Albert Y Lin, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 400.

https://doi.org/10.1182/blood-2021-154323

Published: 2021

Journal Articles

Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition

Yao Yao, Woojun D Park, Eugenio Morelli, MD, Mehmet Kemal Samur, PhD, Nicholas P Kwiatkowski, PhD, Yan Xu, MD, Chandraditya Chakraborty, PhD, Behnam Nabet, PhD, Marta Chesi, PhD, Herve Avet-Loiseau, Nathaniel Gray, Richard A. Young, PhD, Kenneth Anderson, MD, Charles Y Lin, PhD, Nikhil C. Munshi, MD, Mariateresa Fulciniti, PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-142592

Published: 2020

Journal Articles

Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Krish Patel, MD, Radhakrishnan Ramchandren, MD, Michael Maris, MD, Alexander M. Lesokhin, MD, Gottfried R. von Keudell, MD PhD, Bruce D. Cheson, MD, Jeff Zonder, MD, Erlene K. Seymour, MD, Tina Catalano, MSc, Gloria H. Y. Lin, PhD, Bob Uger, PhD, Penka S. Petrova, PhD, Kathleen Roberge, ANP, MSc, Yaping Shou, MDPhD, Swami P. Iyer, MD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136607

Published: 2020

Journal Articles

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142514

Published: 2020

Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Blood (2020) 136 (Supplement 1): 41–43.

https://doi.org/10.1182/blood-2020-136198

Published: 2020

Journal Articles

Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors

Blood (2020) 135 (15): 1255–1269.

https://doi.org/10.1182/blood.2019002922

Published: 2020

Includes: Supplemental data

Journal Articles

AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia

Yajian Jiang, Tianyuan Hu, Tao Wang, Xiangguo Shi, Ayumi Kitano, Kenneth Eagle, Kevin A. Hoegenauer, Marina Y. Konopleva, Charles Y. Lin, Nicolas L. Young, Daisuke Nakada

Blood (2019) 134 (24): 2183–2194.

https://doi.org/10.1182/blood.2019001076

Published: 2019

Includes: Supplemental data

Journal Articles

An Oncogenic Enhancer Encodes Selective Selenium Dependency in AML

Charles Y Lin, PhD, Joanna S. Yi, MD, Yajian Jiang, MBBS, Daisuke Nakada, PhD, Monika Perez, BS, Jost Koren, M.S., Kenneth Eagle

Blood (2019) 134 (Supplement_1): 638.

https://doi.org/10.1182/blood-2019-129433

Published: 2019

NARROW

The Novel Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) Platform Identifies Synergistic Activity of Lanraplenib and Ruxolitinib in Hematological Malignancies

The Combination of Lanraplenib, a Selective SYK Inhibitor, and Gilteritinib, a FLT3 Inhibitor, Targets Aberrant Proliferation and Differentiation Blockade in Acute Myeloid Leukemia

Gut Microbiome Faecalibacterium Abundance in Patients with Plasma Cell Disorders Undergoing Autologous Hematopoietic Stem Cell Transplant Is Associated with Progression Free Survival

Incidence and Outcomes of Cytomegalovirus Reactivation after Chimeric Antigen Receptor T Cell Therapy

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

CDK7 Inhibition Targets Proliferative and Metabolic Oncogenic Vulnerabilities in Multiple Myeloma

Targeting a Putative Intronic Splicing Silencer Salvages Expression from the Recurrent SBDS C.258+2T>C Mutant Allele in Shwachman-Diamond Syndrome Patient Cells and Mouse Model

Preclinical Characterization of NGM936, a Novel Bispecific T Cell Engager Targeting ILT3 for the Treatment of Acute Myeloid Leukemia with Monocytic Differentiation

Increased COVID-19 breakthrough infection risk in patients with plasma cell disorders

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Preclinical Activity of Selective SYK Inhibitors, Entospletinib and Lanraplenib, Alone or Combined with Targeted Agents in Ex Vivo AML Models with Diverse Mutational Backgrounds

CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Inadequate Sars-Cov-2 Vaccine Effectiveness in Patients with Multiple Myeloma: A Large Nationwide Veterans Affairs Study

Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition

Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors

AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia

An Oncogenic Enhancer Encodes Selective Selenium Dependency in AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only